| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892
Activation of T cells requires at least two signals: an antigen-specific signal delivered through the T-cell receptor and a costimulatory signal mediated through molecules designated B7-1 and B7-2. Previous studies have shown that introduction of B7-1 and B7-2 into tumors using retroviral vectors has led to enhanced antitumor effects. A limiting factor for potential clinical applications using this approach is the low efficiency of infection of retroviral vectors and consequent manipulations of infected cells. Vaccinia virus thus represents an alternative vector for B7 gene expression in tumor cells. In this report we describe the construction and characterization of recombinant vaccinia viruses containing the murine B7-1 and B7-2 genes (designated rV-B7-1 and rV-B7-2). Infection of BSC-1 cells with these constructs results in rapid and efficient cell surface expression of both B7-1 and B7-2 (>97% of cells at 4 h). Infection of murine carcinoma cells with low multiplicity of infection of wild-type vaccinia virus leads to the death of the host following tumor transplantation. In contrast, inoculation of rV-B7-1- or rV-B7-2-infected tumor cells into immunocompetent animals resulted in no tumor growth. These studies demonstrate the utility of recombinant vaccinia viruses to deliver B7 molecules to tumor cells for potential gene therapy and recombinant approaches to cancer immunotherapy.
1 To whom requests for reprints should be addressed, at the Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Building 10, Room 8B07, 9000 Rockville Pike, Bethesda, MD 20892.
Received 9/16/94. Accepted 9/29/94.
This article has been cited by other articles:
|
|
 |
|
  X. Zang and J. P. Allison The B7 Family and Cancer Therapy: Costimulation and Coinhibition Clin. Cancer Res., September 15, 2007; 13(18): 5271 - 5279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Tarassoff, P. M. Arlen, and J. L. Gulley Therapeutic vaccines for prostate cancer. Oncologist, May 1, 2006; 11(5): 451 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Liu, P. Hu, L. A. Khawli, and A. L. Epstein Combination B7-Fc Fusion Protein Treatment and Treg Cell Depletion Therapy Clin. Cancer Res., December 1, 2005; 11(23): 8492 - 8502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Loser, A. Scherer, M. B. W. Krummen, G. Varga, T. Higuchi, T. Schwarz, A. H. Sharpe, S. Grabbe, J. A. Bluestone, and S. Beissert An Important Role of CD80/CD86-CTLA-4 Signaling during Photocarcinogenesis in Mice J. Immunol., May 1, 2005; 174(9): 5298 - 5305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Riley and C. H. June The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation Blood, January 1, 2005; 105(1): 13 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. McCart, J. M. Ward, J. Lee, Y. Hu, H. R. Alexander, S. K. Libutti, B. Moss, and D. L. Bartlett Systemic Cancer Therapy with a Tumor-selective Vaccinia Virus Mutant Lacking Thymidine Kinase and Vaccinia Growth Factor Genes Cancer Res., December 1, 2001; 61(24): 8751 - 8757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. von Mehren, P. Arlen, J. Gulley, A. Rogatko, H. S. Cooper, N. J. Meropol, R. K. Alpaugh, M. Davey, S. McLaughlin, M. T. Beard, et al. The Influence of Granulocyte Macrophage Colony-Stimulating Factor and Prior Chemotherapy on the Immunological Response to a Vaccine (ALVAC-CEA B7.1) in Patients with Metastatic Carcinoma Clin. Cancer Res., May 1, 2001; 7(5): 1181 - 1191. [Abstract] [Full Text]
|
|
|
|
|
|
H. Sabzevari, J. Kantor, A. Jaigirdar, Y. Tagaya, M. Naramura, J. W. Hodge, J. Bernon, and J. Schlom Acquisition of CD80 (B7-1) by T Cells J. Immunol., February 15, 2001; 166(4): 2505 - 2513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Maeda, M. Towatari, H. Kosugi, and H. Saito Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells Blood, December 1, 2000; 96(12): 3847 - 3856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Rohrbach, B. Gerstmayer, M. Biburger, and W. Wels Construction and Characterization of Bispecific Costimulatory Molecules Containing a Minimized CD86 (B7-2) Domain and Single-Chain Antibody Fragments for Tumor Targeting Clin. Cancer Res., November 1, 2000; 6(11): 4314 - 4322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stripecke, A. A. Cardoso, K. A. Pepper, D. C. Skelton, X.-J. Yu, L. Mascarenhas, K. I. Weinberg, L. M. Nadler, and D. B. Kohn Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses Blood, August 15, 2000; 96(4): 1317 - 1326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Steele Recent Developments in the Virus Therapy of Cancer Experimental Biology and Medicine, February 1, 2000; 223(2): 118 - 127. [Abstract] [Full Text]
|
|
|
|
|
|
S. Beissert, J. A. Bluestone, I. Mindt, M. Voskort, D. Metze, A. Mehling, T. A. Luger, T. Schwarz, and S. Grabbe Reduced Ultraviolet-Induced Carcinogenesis in Mice with a Functional Disruption in B7-Mediated Costimulation J. Immunol., December 15, 1999; 163(12): 6725 - 6731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Hodge, H. Sabzevari, A. Gomez Yafal, L. Gritz, M. G. O. Lorenz, and J. Schlom A Triad of Costimulatory Molecules Synergize to Amplify T-Cell Activation Cancer Res., November 1, 1999; 59(22): 5800 - 5807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Hodge and J. Schlom Comparative Studies of a Retrovirus versus a Poxvirus Vector in Whole Tumor-Cell Vaccines Cancer Res., October 1, 1999; 59(20): 5106 - 5111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Smythe, P. D. Fink, G. J. Logan, J. Lees, P. B. Rowe, and I. E. Alexander Human Fibroblasts Transduced with CD80 or CD86 Efficiently trans-Costimulate CD4+ and CD8+ T Lymphocytes in HLA-Restricted Reactions: Implications for Immune Augmentation Cancer Therapy and Autoimmunity J. Immunol., September 15, 1999; 163(6): 3239 - 3249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. X. Gnant, A. C. Berger, J. Huang, M. Puhlmann, P. C. Wu, M. J. Merino, D. L. Bartlett, H. Richard Alexander, and S. K. Libutti Sensitization of Tumor Necrosis Factor {{alpha}}-resistant Human Melanoma by Tumor-specific in Vivo Transfer of the Gene Encoding Endothelial Monocyte-activating Polypeptide II Using Recombinant Vaccinia Virus Cancer Res., September 1, 1999; 59(18): 4668 - 4674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. X. Gnant, M. Puhlmann, H. R. Alexander Jr., and D. L. Bartlett Systemic Administration of a Recombinant Vaccinia Virus Expressing the Cytosine Deaminase Gene and Subsequent Treatment with 5-Fluorocytosine Leads to Tumor-specific Gene Expression and Prolongation of Survival in Mice Cancer Res., July 1, 1999; 59(14): 3396 - 3403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Martin, J. G. Frelinger, and J. P.-Y. Ting Combination Gene Therapy with CD86 and the MHC Class II Transactivator in the Control of Lung Tumor Growth J. Immunol., June 1, 1999; 162(11): 6663 - 6670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stremmel, E.A. Greenfield, E. Howard, G.J. Freeman, and V.K. Kuchroo B7-2 Expressed on EL4 Lymphoma Suppresses Antitumor Immunity by an Interleukin 4-dependent Mechanism J. Exp. Med., March 15, 1999; 189(6): 919 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kutubuddin, H. J. Federoff, P. M. Challita-Eid, M. Halterman, B. Day, M. Atkinson, V. Planelles, and J. D. Rosenblatt Eradication of Pre-Established Lymphoma Using Herpes Simplex Virus Amplicon Vectors Blood, January 15, 1999; 93(2): 643 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Challita-Eid, M. L. Penichet, S.-U. Shin, T. Poles, N. Mosammaparast, K. Mahmood, D. J. Slamon, S. L. Morrison, and J. D. Rosenblatt A B7.1-Antibody Fusion Protein Retains Antibody Specificity and Ability to Activate Via the T Cell Costimulatory Pathway J. Immunol., April 1, 1998; 160(7): 3419 - 3426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Dunussi-Joannopoulos, G. Dranoff, H. J. Weinstein, J. L.M. Ferrara, B. E. Bierer, and J. M. Croop Gene Immunotherapy in Murine Acute Myeloid Leukemia: Granulocyte-Macrophage Colony-Stimulating Factor Tumor Cell Vaccines Elicit More Potent Antitumor Immunity Compared With B7 Family and Other Cytokine Vaccines Blood, January 1, 1998; 91(1): 222 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Putzer, M. Hitt, W. J. Muller, P. Emtage, J. Gauldie, and F. L. Graham Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression PNAS, September 30, 1997; 94(20): 10889 - 10894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Dunussi-Joannopoulos, W. Krenger, H. J. Weinstein, J. L.M. Ferrara, and J. M. Croop CD8+ T Cells Activated During the Course of Murine Acute Myelogenous Leukemia Elicit Therapeutic Responses to Late B7 Vaccines After Cytoreductive Treatment Blood, April 15, 1997; 89(8): 2915 - 2924. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
